Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 811, doi. 10.1038/cgt.2012.69
- By:
- Publication type:
- Article
Works matching IS 09291903 AND DT 2012 AND VI 19 AND IP 12
Results: 12
1
2
Suppression of hepatocarcinoma model in vitro and in vivo by ECRG2 delivery using adenoviral vector.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 875, doi. 10.1038/cgt.2012.77
- By:
- Publication type:
- Article
3
HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 888, doi. 10.1038/cgt.2012.79
- By:
- Publication type:
- Article
4
Gene therapy of pancreatic cancer targeting the K-Ras oncogene.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 862, doi. 10.1038/cgt.2012.73
- By:
- Publication type:
- Article
5
Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 822, doi. 10.1038/cgt.2012.65
- By:
- Publication type:
- Article
6
Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 852, doi. 10.1038/cgt.2012.72
- By:
- Publication type:
- Article
7
Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 845, doi. 10.1038/cgt.2012.70
- By:
- Publication type:
- Article
8
Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 870, doi. 10.1038/cgt.2012.76
- By:
- Publication type:
- Article
9
A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 839, doi. 10.1038/cgt.2012.68
- By:
- Publication type:
- Article
10
Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 828, doi. 10.1038/cgt.2012.66
- By:
- Publication type:
- Article
11
Will T-cell therapy for cancer ever be a standard of care?
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 818, doi. 10.1038/cgt.2012.74
- By:
- Publication type:
- Article
12
CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 12, p. 880, doi. 10.1038/cgt.2012.78
- By:
- Publication type:
- Article